Abstract
Cytochrome P450 BM3 (CYP102A1) from Bacillus megaterium is a soluble, catalytically self-sufficient monooxygenase which contains a heme monooxygenase domain and a diflavin reductase domain on a single polypeptide chain. In recent studies, several CYP102A1 mutants were found to generate human metabolites by oxidizing various kinds of drugs. CYP102A1 has therefore become the prime candidate monooxygenase for directed evolution and rational design towards biocatalytic applications. In this study, a set of CYP102A1 mutants were found to oxidize several natural products with chemopreventive potential such as stilbenoids (resveratrol, pterostilbene) and flavonoids (naringenin, genistein), to make human metabolites, mainly monohydroxylated metabolites. These results demonstrate that CYP102A1 mutants can be used to produce human metabolites of natural products, which can be used in several industrial fields including drug development. [This research was supported by Bio-industry Technology Development Program (No. 111052–04–1-SB010), Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea.].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
